Cutler Group LP Immuno Gen, Inc. Put Options Transaction History

Cutler Group LP

12 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q4 2023 Jan 18, 2024	BUY	$12.46 - $29.95 $56,070 - $134,775	4,500 New	4,500 $13,000
Q1 2023 May 01, 2023	SELL	$3.67 - $4.92 $149,736 - $200,736	-40,800 Reduced 97.61%	1,000 $1,000
Q4 2022 Feb 07, 2023	SELL	$4.55 - $6.31 $40,040 - $55,528	-8,800 Reduced 17.39%	41,800 $12,000
Q2 2022 Aug 04, 2022	BUY	$3.15 - $5.76 $75,915 - $138,816	24,100 Added 90.94%	50,600 $75,000
Q1 2022 Apr 14, 2022	BUY	$4.26 - $7.48 $98,406 - $172,788	23,100 Added 679.41%	26,500 $43,000
Q4 2021 Jan 18, 2022	BUY	$4.75 - $7.5 $16,150 - $25,500	3,400 New	3,400 $1,000
Q2 2019 Aug 09, 2019	SELL	$1.8 - $3.3 $18,720 - $34,320	-10,400 Closed	0 $0
Q1 2019 May 10, 2019	BUY	$2.41 - $5.91 $25,064 - $61,464	10,400 New	10,400 $13,000
Q2 2018 Aug 10, 2018	SELL	$9.52 - $12.15 $115,192 - $147,015	-12,100 Closed	0 $0
Q1 2018 May 11, 2018	BUY	$6.7 - $12.95 $43,550 - $84,175	6,500 Added 116.07%	12,100 $5,000
Q4 2017 Jan 17, 2018	SELL	$5.07 - $7.92 $15,210 - $23,760	-3,000 Reduced 34.88%	5,600 $0
Q3 2017 Oct 17, 2017	BUY	$5.4 - $8.47 $46,440 - $72,842	8,600	8,600 $1,000

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.